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Objectives. This study investigated whether insulin response to 
au oral glucose load correlates to acetylcholine-induced coronary 
vasoeonstriction in subjects with vasospastic angina. 
Buckgmund, It has been suggested that coronary vasospasm is 
caused by augmented vascular responsiveness possibly exerted by 
atherosclerosis. Recently, insulin resistance syndrome has been 
proposed as a major promotor of atherosclerotic disease, poten- 
tially enhancing vascular smooth muscular tone. 
Methods. Among subjects with angiographically smooth coro- 
nary arteries, we selected 14 subjects with vasospastic angina and 
14 age- and gender-matched subjects with atypical chest pain. We 
compared coronary vasomotor response to acetylcholine infusion, 
glucose and insulin responses to an oral glucose load (75 g), 
serum iipid concentrations, obesity, heart rate, blood pressure 
and smoking habits in both groups. 
Results. Fasting serum insulin concentrations and insulin 
response were higher in subjects with vasospastic angina than in 
It has been speculated (l-4) that coronary vasospasm plays an 
important role in the pathogenesis of ischemic cardiac events, 
ranging from variant angina to myocardial infarction. Injection 
of acetyicholine causes vasodiiation in a normal coronary 
artery but vasoconstriction in an atherosclerotic or diseased 
coronary artery (5-7). This heterogeneous response to acetyi- 
choline occurs even in angiographlcaiiy smooth coronary ar- 
teries and has been thought to result from early atherosclerosis 
because of the presence of coronary risk factors, such as male 
gender, age, hypercholesteroiemia and hypertension (8-11). 
Insulin resistance syndrome has been proposed as a major 
promoter of atherosclerotic disease (12,13). Thus obesit-y, 
hypertension, glucose intolerance and disiipidemia have been 
suggested to promote atherosclerosis, with insulin resistance 2s 
the underlying intermediary. Furthermore, earlier studies have 
implied that hyperinsulinemia itself may enhance coronary 
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-- 
those with atypical chest pain; however, glucose tolerance, nbesity, 
heart rate, blood pressure and smoking habits did nol differ 
between groups. In subjects with vasospastic angina, nearly all 
coronary segiztents, except distal segments of the IeR circumtiex 
coronary artery, were constricted at peak acetylcholine infusion 
(20 to 100 pg), whereas all segments were dilated in subjects with 
atypical chest pain. Regression analysis for both groups demon- 
strated a correlation between coronary vasoconstriction and fast- 
ing serum insulin concentrations (r = 0.52, p C O.Ol), insulin 
response (r = 0.71, p c O.OOl), serum triglyceride concentrations 
(r = 0.51, p < 0.05) and atherogenic index (r = 0.44, p < 0.05). 
Cottclusions. Results show that acetylcholine-induced coronary 
vasoconstriction in subjects with vasospastic angina correlates 
with hyperinsulinemia and enhanced insulin response, suggesting 
insulin resistance syndrome as a feature of vasospastic angina. 
(J Am Golf Cardiol1995;25:356- 61) 
-_ 
vnsomotor tone through sympathetic nerve activation (14,15), 
hypertrophic effects on smooth muscle ceils (l&17) or modi- 
fication of intracellular cation metabolism (18-20). Therefore, 
in;u!in resistance syndrome, at least in Fart, is speculated to 
relate to vasospastic angina through augmenting atherosciero- 
sis or coronary vascular tone, or both. 
To investigate whether insulin resistance syndrome corre- 
I,ates to coronary vasospasm, we evaluated coronary vasomotor 
response to acetyichoiine and insulin response to a glucose 
load in angingraphicaiiy normal subjects with vasospastic an- 
gin2 or atypical chest pain. 
Methods 
St!idy subjects. We studied 14 subjects with vasospastic 
angina and 14 control subjects with atypical chest pain. Sub- 
jects with vasospastic angina had a spontaneous episode of 
angina pectoris at rest accompanying ischemic eiectrocardio- 
graphic (ECG) changes and demonstrated X0% vasoconstric- 
tion by acetyicholine infusion in one or more segments of 
epicardial coronary arteries with ischemic ST segment changes. 
Age- arrd gender-matched control subjects had atypical chest 
pdin without ischemic ECG changes or acetylcholine-induced 
vasospasm. Subjects from both groups were included if they 
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had angiographically normal coronary arteries to eliminate the 
dominant effect of atherosclerosis on the angiogram. All 
subjects showed no evidence of arrythmia, valvular heart 
dise Y Y contractile dysfunction. Additionally, subjects with 
plasi ,c glucose concentrations of ~6.7 mmohliter (120 mgldl) 
at istmb md cl 1.1 mmoliliter (200 mgldl) 120 min after a 
75-g oral giucost load were includes! tc omit possible deficits of 
insulin secretion in subjects with severe glucose intolerance. 
Other criteria for inclusion were age 40 to 69 years; no history 
of renal, hcpatic and endocrine disorders; and no current 
medication that affects insulin sensitivity, such as thiazides and 
alpha- and beta-blockers. Written informed consent was ob- 
tained from all patients after the study protocol was explained. 
Coronary vasomotcr response to acetyhzhcline infusion. 
All patients stopped taking calcium channel blocking agents 
and long-acting nitrates at least 12 h before cardiac catheter- 
ization. After a standard protocol of right- ano left-sided 
cardiac catheterization and coronary angiography, coronary 
vasomotor response to acetylcholine infusion was studied as 
follows. First, a pacing catheter set in the demand mode of 50 
beats/min was placed in the right ventricular apex. Through 7F 
right and left Judkins catheters, graded doses of acetylchoiine 
chloride (Dai-ichi Pharmaceutical Co., Tokyo, Japan) dis- 
solved in 5 ml of saline solution were infused manually at 
5 ml/30 s. Acetylchoiine was infused at 20 and 50 pg in the right 
coronary at tery and at 20,50 and 100 cL& in the left coronary 
artery. After acetylcholine-induced vasospasm occurred, the 
higher dosage of acetylchoiine was discontinued. Throughout 
the study protocol, heart rate, aortic pressure and the ECG 
were monitored continuously. 
When acetylcholine-induced vasospasm (>50% of vasocon- 
striction in one or more segments of epicardial coronary 
arteries) with ischemic ECG changes (>l-mV ST segment 
depression or elevation) occurred, or, if not, 3 min after each 
acetylcholine injection, coronary angiograms were recorded on 
35-mm cinefilm (30 frames/s) with a cineangiographic system 
(Sim Trac, Siemens, Erlangen, Germany). A volume of 8 1~1 
10 ml nonionic contrast medium (Omnipaque 350, Dai-ilhi 
Pharmaceutical Co.) was injected into the coronary arteries at 
4 to 5 ml/s. The optimal view for recording was care.:lly 
chosen based on the baseline angiogram, and that same 
position was used to document subsequent angiograms After 
calibration with scaled grids in the fields of view, lumen 
diameters were measured with a caliper at end-diastole in the 
proximal, middle and distal segments of the left anterior 
descending and right coronary arteries and the proximal and 
distal segments of the left circumflex coronary artery. In each 
segment, the portion that exhibited the maximal change in 
diameter at peak acetylcholine dosage was chosen for subse- 
quent measurement. Coronary vasomotor response to acetyl- 
choline infusion was expressed as percent change in coronary 
artery diameter corrected for infused acetylcholine: % Change 
in coronary artery diameter = (Dafter - Dbefore) X 100/D,,,,,/ 
-log[Acetylcholine (mol)], where Dafter and Dberore = diam- 
eter before and after peak acetylcholine infusion (10). In this 
formula, positive and negative values reflect vasodilation and 
vasoconstriction, respectively. The sum of the percent diame- 
ter changes in eight coronary segments (sum of % diameter 
changes in coronary segments/-log[Acetylchcline (mol)]) was 
used to assess total coronary vasomotor responses to acetyl- 
choline. 
Definition of risk factors. We measured the following risk 
factors 1 or 2 days before cardiac catheterization: plasma 
glucose and serum insulin responses to a glucose load (75 g), 
serum lipid concentrations, obesity, heart rate, blood pressure 
and current smoking habits. Heavy physical exercise, smoking 
and caffeine were restricted in all subjects for 2 days before the 
study. After an overnight fast, a 75g oral glucose loading test 
was performed between 8 and 10 AM. Glucose and insulin areas 
were defined as follows: glucose or insulin area (mmol*hRer 
or $J*h/ml) = 0.25 X (C, + C120) + 0.5 X (C,,, + C, f C,,), 
where C,,30,60,90,120 = plasma glucose or serum insulin concen- 
trations before and 30,60,90 and 120 min after a glucose load. 
Plasma glucose was determined with an autoanalyzer (model 
736-60. Hitachi Medical Corporation, Tokyo, Japan) using a 
glucose oxidase method (Quickauto Neo Glu HK, Shinotest 
Co., Tokyo, Japan). and serum insulin was measured by 
radioimmunoassay using an anti-human insulin antibody (AB 
insulin beads, Eiken Co., Tokyo, Japan). After an overnight 
fast, serum concentrations of total cholesterol, triglycerides 
and high density lipoprotein (HDL) cholesterol fractionated 
using dextrdn magnesium sulfate were measured with enzy- 
matic methods. Low density lipoprotein (LDL) cholesterol was 
calculated as follows: LDL cholesterol = Total cholesterol - 
HDL cholesterol - Triglyceride concentrations/5. Apolipopro- 
tein A-I, A-II, B, C-II, C-III and E were measured with a single 
radial immunodifhtsion method. Body mass index was defined 
as the weight/height’ ratio (kg/m2). Steady state blood pressure 
and heart rate were recorded in duplicate in the supine 
position after at least a 12-h cessation of medication. Current 
smoking habits were assessed by the index :R: cigaretms 
smoked/day X years. 
St;rtistical analysis. Results are expressed as meh I?. value 2 
SEM. Two-taiied unpaired Student I and Fisher exa;:t proba- 
bility tests were used to compare group mean vaiues.\Glucose 
and insulin responses to a glucose load were compared be- 
tween groups using two-way analysis of variance and within a 
group by one-way analysis of variance for repeated mk:asures 
followed by a Bonferroni multiple comparison test. SirnIle and 
stepwise multiple regression analyses were performed 43 test 
correlations between total coronary vasomotor respons.: and 
risk factors in both groups. A p value < 0.05 was considered 
significant. 
Results 
clinical characteristics. The two study groups did not 
differ in body mass index, heart rate, blood pressure and 
cigarette smoking habits (Table 1). Obesity (body mass index 
>25 kg/m”), hypertension (systolic blood pressure >160 mm Hg 
or diastolic blood pressure >95 mm Hg, or both) and cigarette 
smokmg (cigarettes smoked/day x year >400) analyzed with the 
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Table 1. Ciinical Characteristics in Subjects With Vasospastic 
Angina or Atypical Chest Pam 
%e W 
Gender (M/F) 
Body mass index (kg/m*) 
Heart rate (beatslmin) 
Blood pressure (mm Hg) 
Smoking (cigarettes/day 
x year) 
Subjects With Subjects With 
Atypical Chest Pain Vasospastic Angina 
(n = 14) (n = 14) 
54 2 2 52 2 3 
117 B/6 
24.1 t 0.6 23.,1 i: 0.7 
73 2 4 48 2 4 
139179 -c 814 133177 + 813 
144269 281 2 125 
Data presented are mean value lr SEM or number of patients. F = female; 
M = male. 
Fisher exact probability test also showed no significant difference 
between groups (data not shown). Serum concentrations of total, 
WDL and LDL cholesterol, triglycerides and apolipoproteins and 
atherogenic index did not differ between the groups (Table 2). 
Glucose and insulin responses. Plasma glucose and serum 
insulin responses to an oral glucose load (75 g) are shown in 
Figure 1. Fasting plasma glucose concentration and glucose 
reqpcnse (expressed by peak glucose concentration and glu- 
case area) were similar between both groups (Table 3). 
However, fasting serum insulin concentration and insulin 
response (expressed by peak insulin concentration, insulin 
area, insulin area/glucose area and insulinogenic index) were 
significantly higher in subjects with vasospastic angina than in 
those with atypical chest pain. 
Coronary vasomotor response to acetylcholine. All 14 sub- 
jects with vasospastic angina had acetylcholine-induced vaso- 
constriction >50% with ischemic ST segment changes (the left 
anterior descending coronary artery in 8 [2 with vasoconstric- 
tion Ml%]; the right coronary artery in 5 [l with vasocon- 
striction >90%]; and the left anterior descending and right 
Table 2. Serum Concentrations of Cholesterol, Triglycerides and 
Apolipoproteins in Subjects With Vasospasiic Angina or Atypical 
Chest Pain 
-. 
Subjects With Subjects With 
Atypical Chest Pain Vasospastic Anpina 
(n = 14) (n = 14) 
Total cholesterol (mmoliliter) 5.69 i 0.28 5.74 -c 0.27 
HDL (mmolfliter) 1.40 + 0.08 1.33 It 0.13 
LDL (mmol/liter) 3.59 + 0.23 3.57 it 0.23 
Triglycerides (mmomiter) 1.53 + 0.14 1.96 or 0.29 
Apo-AI (mg/lOO ml) I34 2 8 137 r 9 
Apo-AIl (mg/lOO ml) 32 + 2 33 2 3.0 
APO-B (mgi100 ml) 186 2 4 97% 11 
APO-Cl1 (mgl:Nl ml) 3.50 ?I 0.40 4.36 f 0.58 
ApoX (mg/lOO ml) 7.3 + 0.8 11.0 It I.7 
Ape-E (mg/lOO ml) 5.40 It. 0.90 6.70 c 0.70 
Atherogenic index 3.10 + 0.19 3.80 + 0.50 
Data presented are mean value 2 SEM. Apo = apolipoprotein; Atherogenic 
index = (Total cholesterol - High density lipoprotein [HDL] cholesteroI)/HDL 
cholesterol; LDL = low density lipoprotein cholesterol. 
Time (min) Time (min) 
Figure 1, Plasma glucose (left) and serum insulin (right) responses to 
an oral glucose load (?5 g) in subjects with vasospastic angina (solid 
circles, n = 14) or atypical chest pain (open circles, n = 14). Data 
represent mean value :t SEM. Two-way analysis of variance between- 
group p vaiues are shown. 
coronary arteries in 1). Subjects with atypical chest pain 
showed vasodilation of the right (acetylcholine up to 50 pg) 
and left (acetylcholine up to 100 pg) coronary arteries. Group 
mean coronary diameter changes during acetylcholine infusion 
are shown in Figure 2. Subjects with vasospastic angina showed 
vasoconstriction of nearly all segments except for distal seg- 
ments of the left circumflex coronary artery, whereas those 
with atypical chest pain had vasodilation of all segments at the 
maximal dose of acetylcholine. Total coronary vasomotor 
response to acetylcholine ranged from -40.2 to -6.7 (- 18.4 ? 
9.5) in subjects with vasospastic angina and from 32.2 to 2.4 
(11.2 2 8.4) in those with atypical chest pain. 
Multiple regression analysis. Simple regression analysis 
for both groups also indicated that age, body mass index, heart 
rate (data not shown), systolic and diastolic blood pressures 
and fasting plasma glucose concentrations did not correlate 
with total coronary vasomotor response to acetylcholine (Fig. 
3). On the contrary, the analysis demonstrated that total 
coronary vasomotor response to acetylcholine significantly 
correlated with serum fasting (r = -0.52, p < 0.01) and peak 
insulin concentrations (r = -0.71, p < O.OOl), insulin area (r = 
-0.71, p < O.OOl), insulin area/glucose area (r = -0.71, p < 
Table 3. Plasma Glucose and Serum Insulin Responses to an Oral 
Glucose Load (75 g) in Subjects With Vasospastic Angina or 
Atypical Chest Pain 
Subjects With Subjects With 
Atypical Chest Pain Vasospastic Angina 
(11 = 14) (n = 14) 
Fasting plasma glucose (mmol/liter) 4.87 2 0.10 5.12 t 0.09 
Fasting plasma insulin (PUlml) 6.5 I 0.8 10.2 + 1.4” 
Peak plasma glucose (mmol/Iiter) 9.10 2 0.62 9.90 i: 0.44 
Peak plasma insulin (@U/ml) 44r7 123 t 2st 
Glucose area (mmol*hAiter) 14.8 ;r 0.9 16.7 t 0.7 
Insulin area ($+/mliter) 61 ? 10 161 t 31t 
Insulin area/glucose area 3.99 -c 0.53 9.24 t 1.44t 
Insulinogenic index 0.54 t 0.13 1.05 t 0.15* 
“p < 0.05, tp < 0.01 versus subjects with atypical chest pain. Data presented 
are mean value t SEM. 
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Subjects with atypical chest pain 
Subjects with vasospastic angina 
-8.0 J J 
prox mid dist P,OX mid dist prox dist 
RCA LAD LCX 
Coronary Segments 
Figure 2. Coronary artery diameter responses to acetylcholine infu- 
sion in subjects with vasospastic angina (open bars, n = 14) or atypical 
chest pain (dotted bars, n = 14). Data represent mean value _f SEM. 
*Significantly different from the corresponding values in subjects with 
atypical chest pain (p < 0.01). dist = distal; LAD = left anterior 
descending coronary artery; LCX = left circumflex coronary artery; 
mid = middle: prox = proximal; RCA = right coronary artery. 
O.OOl), insulinogenic index (r = -0.46, p < 0.05) and glucose 
area (r = -0.52, p < 0.01) (Fig. 4). Plasma triglyceride 
concentrations and atherogenic index were also related to total 
coronary vasomotor response (Fig. 5). Stepwise multiple re- 
gression analysis showed that only insulin area correlated with 
total coronary vasomotor response (standard coefficient 
-0.732, p < 0.001). Values not included in the model were age 
(partial coefficient -0.030), body mass index (-0.248), systolic 
Figure d. Correlation between total coronary vasomotor response to 
acetylcholine and age (A), body mass index (B) and systolic (C) and 
diastolic (D) blood pressure in subjects with angiographically normal 
coronary arteries. Total coronary vasomotor response to acetylcholine 
is expressed as sum of percent diameter changes in eight coronary 
segments/-log [acetylcholine (mol)], where positive and negative 
values reflect vasodilation and vasoconstriction, respectively. n.p. = 
not predictable. 
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Figure 4. Correlation between tc’al coronary vasomotor I ssponse to 
acetylcholine and fasting plasma glucose concentrations (A), glucose 
area (B), serum insulin concentrations (C) and insulin areas (D) in 
subjects with angiographically normal coronary arteries. Total coro- 
nary vasomotor response to acetylcholine and positive and negative 
values as in Figme 3. n.p. = not predictable. 
blood pressure (0.074), smoking habits (-0.23.Q glucose area 
(-0.036) and total cholesterol (-0.050) and triglyceride 
(-0.096) concentrations. For the final regression model, total 
coronary vasomotor response to acetylcholine was -0.129 X 
(Insulin area) f 12.48 (Adjusted R2 = 0.514). 
Discussion 
In this study, angiographically normal subjects with vaso- 
spastic angina demonstrated hyperinsulinemia and enhanced 
insulin response to an oral glucose load. Regression analysis in 
subjects with vasospastic angina or atypical chest pain showed 
that acetylcholine-induced vasoconstriction correlated with 
fasting serum insulin concentrations, insulin response and 
serum triglyceride concentrations but not with obesity, heart 
rate, blood pressure or smoking habits. 
Coronary vasospasm and atherosclerosis. Coronary vaso- 
spasm has been hypothesized to depend on the extent of 
atherosclerosis beCalJSe predictors for vasospastic angina or 
acetylcholine-induced vasoconstriction are similar to coronary 
risk factors for atherosclerosis (6-11). Impaired release of 
endothelium-derived relaxing factor (EDRF) has been re- 
ported in atherosclerotic coronary arteries, suggesting 
atherosclerosis-elicited endothelial dysfunction as a cause of 
coronary vasospasm (21,22). However, several investigators 
(23,24) have reported preserved endotheliumdependent vaso- 
dilation in vasospastic sites in patients with vasospastic angina, 
implicating coronary vasospasm mainly on the basis of a 
supersensitivity of vascular smooth muscle. An augmented 
contractility of vascular smooth muscle has been shown to be 
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Figure 5. Correlation between total coronary vasomotor esponse to 
acetylcholine and serum total cholesterol (A), triglyceride (B) and high 
density lipoprotein (HDL) cholesterol (C) concentrations and athero- 
genie index [(Total cholesterol - HDL cholesterol)/HDL cholesterol] 
(D) in subjects with angiographically normal coronary arteries. Total 
coronary vasomotor esponse to acetylcholine and positive and nega- 
tive values as in FiglIve 3. n.p. = not predictable. 
evoked by atherosclerosis (25). The atherosclerosis-elicited 
hyperreactivity of vascular smooth muscle may play some role 
in the pathogenesis of coronary vasospasm (26). 
Insulin I esistance syndrome and atherosclerosis. Even 
were overt hyperglycemia not established, hyperinsuiinemia 
and increazd responses in plasma glucose and insulin obvi- 
ously suggest the involvement of insulin resistance in subjects 
with vasospastic angina (27). Insulin resistance syndrome 
was observed to be a significant contributor to atherogenesis 
when acccmpanied by other risk factors, namely glucose 
intolerance, disiipidemia, obesity and hypertension (12,i3). Up 
to now serum tota! cholesterol (9-11) and apoiipoprotein 
concentrations (28,29) have been considered indicators for 
acetyichoiine-induced vasoconstriction or vasospastic angina. 
However, the present study demonstrated that serum trigiyc- 
eride concentrations and atherogenic index, regardless of total 
cholesterol or apoiipoprotein concentrations, correlated with 
acetyichoiine-induced vasoconstriction (30). Numerous studies 
(27,31-34) have shown that insulin resistance syndrome affects 
lipoprotein metabolism through several mechanisms. Thus, 
insulin stimulates hepatic very low density lipoprotein choies- 
teroi (VLDL) secretion, whereas peripheral insulin resistance 
causes a reduced breakdown of triglyceride-rich lipoprotein 
and a decrease in HDL cholesterol synthesis (33). Also, an 
increase in atherogenic small, dense LDL (27,32) and stimu- 
lated uptake of LDL receptor-mediated cholesterol (34) have 
been demonstrated. In fact, regression analysis in the present 
study subjects revealed that fasting serum insulin concentra- 
tions and insulin area correlated with plasma triglyceride 
(r = 0.51, p < 0.01; r = 0.65, p < 0.001, respectively) and HDL 
cholesterol (r = -0.49, p < 0.01; r = -0.41; p < 0.05) 
concentrations and atherogenic index (r = 0.67, p < 0.001; r = 
67, p < 0.001). In vitro studies have demonstrated that insulin 
exerts a direct hypertrophic effect on both vascular endothe- 
iium and smo& muscle ceils (16,17). Insulin resistance syn- 
drome may promote atherogenesis through disiipidemia or 
primary hypertrophic effects, or both, involving a vasospastic 
response to acetyichoiine through an augmented contractility 
of vascular smooth muscle, although abnormal lipid metabo- 
lism itself could he considered a cause of acetyichoiine-induced 
w.oconstriction (9-11). 
Insulin and coronary vasomotor tone. Another possible 
mechanism for a correlation between hyperinsuiinemia and 
acetyichoiine-induced vasoconstriction is the finding that hy- 
perinsuiinemia itself may augment coronary vasomotor tone. 
Yanagisawa-Miwa et al. (35) demonstrated that a thrombox- 
ane A, anaiogue accentuated contraction of the coronary 
artery preincubated with a physiologic concentration of insulin 
(30 to 300 pU/mi). Because attenuation had been observed 
only at lower concentrations of Mg” (0.5 to 1.5 mmoifliter), 
these investigators (35) hypothesized that Mg’+-modulated 
insulin action on glucose uptake and Ca2+ metabolism was the 
mechanism. An earlier study (36) reported that thromboxane 
B,, an inactive metaboiite of thromboxane AZ, was increased in 
the peripheral and coronary sinus blood of patients with 
vasospastic angina and suggested thromboxane A2 as a possi- 
ble mediator of coronary vasospasm. Furthermore, insulin has 
been demonstrated to modify intracellular cation metabolism, 
presumably through the mechanism of inhibited Ca’+/Mg*+ 
ATPase and stimulated Ca2’/Naf exchanger activities (18- 
20). A potential alteration in intracellular calcium metabolism 
may modulate coronary vasomotor tone (27,37). Recently, 
hyperinsuiinemia has been implicated in the pathogenesis of 
microvascular angina (syndrome X) (38-40). The term syn- 
drome X refers to patients with angiographicaliy normal 
findings who have angina1 chest pain and positive exercise test 
results on the ECG. The presence of the insulin-resistant state 
in coronary vasospasm and syndrome X may indicate similar 
underlying mechanisms despite their different clinical manifes- 
tations. 
Conclusions. The present study demonstrated that hyper- 
insuiinenna and an enhanced insulin response to an orai 
glucose load correlated with acetyichoiine-induced vasocon- 
striction in srlbjects with vasospast;c angina. Although the role 
of the insulin-resistant state in the pathogenesis of coronary 
vasospasm cannot be ascertained on the basis of this study, we 
may speculate that insulin resistance syndrome is a feature of 
vasospastic angina. Further studies are necessary to elucidate 
the role of insulin resistance syndrome in the development or 
modification of coronary vasospasm. 
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